dwinnex.com

Clovis Oncology, Inc. [NASDAQ:CLVS]: Analyst Rating and Earnings

Stock traders often pay close attention what Wall Street analysts have to say about a potential investment. For Clovis Oncology, Inc. [CLVS], the latest consensus recommendation available followed its financial results for the fiscal quarter ending in December. On average, stock market experts give CLVS an Outperform rating. Its stock price has been found in the range of 11.50 to 52.15. This is compared to its latest closing price of $17.07.

Wall Street analysts provide their ratings on a scale of 1 to 5, and the current average score for Clovis Oncology, Inc. [CLVS] is sitting at 2.00. This is compared to 1 month ago, when its average rating was 2.00.

For the quarter ending in Mar-19 Clovis Oncology, Inc. [CLVS] generated $0.03 billion in sales. That’s 2.73% higher than the average estimate of $0.03 billion as provided by Wall Street analysts. The three indicators above suggest that overall, this stock is demonstrating a mixed bag of positive appeal and some drawbacks, making it a somewhat risky investment that also has the potential to generate high ROI in the long run.

Keep an eye out for the next scheduled publication date for this company’s financial results, which are expected to be released on Wed 7 Aug (In 79 Days).

Fundamental Analysis of Clovis Oncology, Inc. [CLVS]

Now let’s turn to look at profitability: with a current Operating Margin for Clovis Oncology, Inc. [CLVS] sitting at -349.95 and its Gross Margin at +76.86.

This company’s Return on Total Capital is -47.86, and its Return on Invested Capital has reached -50.10%. Its Return on Equity is -143.16, and its Return on Assets is -45.99. These metrics suggest that this Clovis Oncology, Inc. does a poor job of managing its assets, and likely won’t be able to provide successful business outcomes for its investors in the near term.

Turning to investigate this organization’s capital structure, Clovis Oncology, Inc. [CLVS] has generated a Total Debt to Total Equity ratio of 393.60. Similarly, its Total Debt to Total Capital is 79.74, while its Total Debt to Total Assets stands at 66.62. Looking toward the future, this publicly-traded company’s Long-Term Debt to Equity is 392.90, and its Long-Term Debt to Total Capital is 79.60. This company is not leveraging its assets to take on debt, which stunts its growth and limits the ROI for investors.

What about valuation? This company’s Enterprise Value to EBITDA is -2.92. The Enterprise Value to Sales for this firm is now 8.74, and its Total Debt to Enterprise Value stands at 0.58. Clovis Oncology, Inc. [CLVS] has a Price to Book Ratio of 6.47.

Shifting the focus to workforce efficiency, Clovis Oncology, Inc. [CLVS] earns $203,821 for each employee under its payroll. Similarly, this company’s Receivables Turnover is 8.16 and its Total Asset Turnover is 0.12. This publicly-traded organization’s liquidity data is also interesting: its Quick Ratio is 4.34 and its Current Ratio is 4.55. This company, considering these metrics, has a healthy ratio between its short-term liquid assets and its short-term liabilities, making it a less risky investment.

Clovis Oncology, Inc. [CLVS] has 56.17M shares outstanding, amounting to a total market cap of $958.82M. Its stock price has been found in the range of 11.50 to 52.15. At its current price, it has moved by -68.30% from its 52-week high, and it has moved 43.74% from its 52-week low.

This stock’s Beta value is currently 1.89, which indicates that it is more volatile that the wider market. This stock’s Relative Strength Index (RSI) is at 28.29. This stock, according to these metrics, is currently Oversold.

Conclusion: Is Clovis Oncology, Inc. [CLVS] a Reliable Buy?

Clovis Oncology, Inc. [CLVS] stock is presenting a less attractive investment opportunity when compared to similarly-sized corporations in the same industry. The price performance of these shares has not shown much promise, and the financial results that this company has recently delivered present a highly risky investment.